Electra Therapeutics, Inc. (NASDAQ:ETRA – Get Free Report) Director Orbimed Advisors Llc purchased 245,113 shares of the firm’s stock in a transaction dated Tuesday, November 3rd. The shares were acquired at an average cost of $7.86 per share, with a total value of $1,926,588.18. Following the completion of the purchase, the director directly owned 5,175,604 shares in the company, valued at approximately $40,680,247.44. This represents a 4.97% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Orbimed Advisors Llc also recently made the following trade(s):
- On Thursday, November 5th, Orbimed Advisors Llc acquired 156,091 shares of Electra Therapeutics stock. The stock was acquired at an average cost of $7.31 per share, for a total transaction of $1,141,025.21.
- On Wednesday, November 4th, Orbimed Advisors Llc acquired 71,367 shares of Electra Therapeutics stock. The stock was acquired at an average cost of $7.53 per share, for a total transaction of $537,393.51.
- On Monday, September 21st, Orbimed Advisors Llc bought 1,333,333 shares of Electra Therapeutics stock. The shares were acquired at an average price of $15.00 per share, with a total value of $19,999,995.00.
Electra Therapeutics Stock Performance
ETRA traded down $0.62 during trading hours on Thursday, hitting $7.35. 524,786 shares of the company’s stock were exchanged, compared to its average volume of 481,923. Electra Therapeutics, Inc. has a 1-year low of $6.86 and a 1-year high of $15.50.
Wall Street Analysts Forecast Growth
ETRA has been the subject of a number of recent research reports. Jefferies Financial Group assumed coverage on shares of Electra Therapeutics in a research note on Tuesday, October 13th. They set a “buy” rating and a $32.00 price objective for the company. Wall Street Zen upgraded Electra Therapeutics to a “hold” rating in a report on Saturday, September 26th. Cantor Fitzgerald initiated coverage on Electra Therapeutics in a research report on Tuesday, October 13th. They issued an “overweight” rating on the stock. Evercore assumed coverage on Electra Therapeutics in a report on Tuesday, October 13th. They set an “outperform” rating and a $36.00 target price on the stock. Finally, HC Wainwright initiated coverage on Electra Therapeutics in a research report on Monday, October 26th. They set a “buy” rating and a $30.00 price target for the company. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $33.50.
Check Out Our Latest Stock Report on Electra Therapeutics
Electra Therapeutics Company Profile
Electra Therapeutics, Inc (NASDAQ: ETRA) is a clinical-stage biotechnology company focused on developing antibody-based medicines for diseases driven by abnormal immune-cell activity. The company’s approach is designed to selectively eliminate or modulate disease-causing immune cells while preserving healthy immune function.
Electra’s lead investigational product is ELA026, an antibody targeting SIRPĪ±, a protein involved in immune-cell signaling. The company is evaluating ELA026 in immune-mediated diseases, including systemic sclerosis and other conditions in which macrophages and related immune cells may contribute to disease progression.
Featured Stories
- Five stocks we like better than Electra Therapeutics
- Google’s Credit Backstop May Be TeraWulf’s Biggest Advantage
- Could the Midterms Revive Medicare for All? 3 Healthcare Stocks to Watch
- Qualcomm Beat Earnings, But Its Fastest-Growing Businesses Have a Catch
- Oil, Uranium, or Renewables? 3 Energy Plays for a Changing Market
Receive News & Ratings for Electra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Electra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
